R&D Spending Showdown: TG Therapeutics, Inc. vs Xencor, Inc.

Biotech R&D: Xencor's Aggressive Growth vs. TG Therapeutics

__timestampTG Therapeutics, Inc.Xencor, Inc.
Wednesday, January 1, 20143135478118516000
Thursday, January 1, 20154344581734140000
Friday, January 1, 20166648982051872000
Sunday, January 1, 20179688613471772000
Monday, January 1, 201815379300097501000
Tuesday, January 1, 2019148369000118590000
Wednesday, January 1, 2020151934000169802000
Friday, January 1, 2021198532000192507000
Saturday, January 1, 2022112128000199563000
Sunday, January 1, 202376192000253598000
Loading chart...

Unleashing the power of data

R&D Spending Trends: TG Therapeutics vs. Xencor

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, TG Therapeutics, Inc. and Xencor, Inc. have been at the forefront of this race. From 2014 to 2023, Xencor's R&D expenses surged by over 1,270%, peaking in 2023 with a 37% increase from the previous year. Meanwhile, TG Therapeutics saw a more modest growth of approximately 143% over the same period, with a notable peak in 2021.

This data highlights Xencor's aggressive investment strategy, particularly in recent years, as it outpaced TG Therapeutics in R&D spending. Such financial commitments are pivotal for breakthroughs in drug development and maintaining a competitive edge. As these companies continue to innovate, their R&D investments will likely play a crucial role in shaping the future of biotechnology.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025